Related Experiment Video
Updated: Jan 12, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Design and development of 5'-modified 7-substituted 4'-thionucleosides as potent Haspin inhibitors: Synthesis and
Yun A Yum1, Sung Chul Jang1, Seung Woo Kim1
1Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Abstract:
Haspin, a serine/threonine kinase essential for proper chromosome alignment during mitosis, has emerged as a promising anticancer target due to its selective function in proliferating cells. In our previous study, we identified LJ-4827, a 7-acetylene-substituted 4'-thionucleoside analog bearing a 5'-azido group, as a potent Haspin inhibitor with significant antiproliferative effects. To further optimize activity, we synthesized a series of novel 4'-thionucleoside analogs with 7-substituted scaffolds and diverse 5'-position modifications, as well as selected 6-position derivatives. SAR analysis revealed that incorporation of a 7-cyano group together with small, polar 5'-substituents such as azido (1c) or amino (1d) provided the most potent Haspin inhibition, with compound 1c achieving subnanomolar potency (IC50 = 0.26 nM). Importantly, the 5'-amino analog 1d exhibited moderate Haspin inhibition (IC50 = 18 nM), together with a highly selective kinase inhibition profile and markedly improved aqueous solubility relative to 1c. These properties enabled in vivo evaluation, where 1d significantly suppressed tumor growth in a colorectal cancer xenograft model, with comparable efficacy observed following either intraperitoneal or oral administration. These findings highlight 1d as a particularly promising Haspin-targeted anticancer agent that combines potent activity with favorable drug-like properties.
More Related Videos
15:22Nucleoside Triphosphates - From Synthesis to Biochemical Characterization
Published on: April 3, 2014
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015